Cargando…
A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance
BACKGROUND: The virus SARS-CoV-2 can exploit biological vulnerabilities (e.g. host proteins) in susceptible hosts that predispose to the development of severe COVID-19. METHODS: To identify host proteins that may contribute to the risk of severe COVID-19, we undertook proteome-wide genetic colocalis...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457835/ https://www.ncbi.nlm.nih.gov/pubmed/34402426 http://dx.doi.org/10.7554/eLife.69719 |
_version_ | 1784571188117241856 |
---|---|
author | Anisul, Mohd Shilts, Jarrod Schwartzentruber, Jeremy Hayhurst, James Buniello, Annalisa Shaikho Elhaj Mohammed, Elmutaz Zheng, Jie Holmes, Michael Ochoa, David Carmona, Miguel Maranville, Joseph Gaunt, Tom R Emilsson, Valur Gudnason, Vilmundur McDonagh, Ellen M Wright, Gavin J Ghoussaini, Maya Dunham, Ian |
author_facet | Anisul, Mohd Shilts, Jarrod Schwartzentruber, Jeremy Hayhurst, James Buniello, Annalisa Shaikho Elhaj Mohammed, Elmutaz Zheng, Jie Holmes, Michael Ochoa, David Carmona, Miguel Maranville, Joseph Gaunt, Tom R Emilsson, Valur Gudnason, Vilmundur McDonagh, Ellen M Wright, Gavin J Ghoussaini, Maya Dunham, Ian |
author_sort | Anisul, Mohd |
collection | PubMed |
description | BACKGROUND: The virus SARS-CoV-2 can exploit biological vulnerabilities (e.g. host proteins) in susceptible hosts that predispose to the development of severe COVID-19. METHODS: To identify host proteins that may contribute to the risk of severe COVID-19, we undertook proteome-wide genetic colocalisation tests, and polygenic (pan) and cis-Mendelian randomisation analyses leveraging publicly available protein and COVID-19 datasets. RESULTS: Our analytic approach identified several known targets (e.g. ABO, OAS1), but also nominated new proteins such as soluble Fas (colocalisation probability >0.9, p=1 × 10(-4)), implicating Fas-mediated apoptosis as a potential target for COVID-19 risk. The polygenic (pan) and cis-Mendelian randomisation analyses showed consistent associations of genetically predicted ABO protein with several COVID-19 phenotypes. The ABO signal is highly pleiotropic, and a look-up of proteins associated with the ABO signal revealed that the strongest association was with soluble CD209. We demonstrated experimentally that CD209 directly interacts with the spike protein of SARS-CoV-2, suggesting a mechanism that could explain the ABO association with COVID-19. CONCLUSIONS: Our work provides a prioritised list of host targets potentially exploited by SARS-CoV-2 and is a precursor for further research on CD209 and FAS as therapeutically tractable targets for COVID-19. FUNDING: MAK, JSc, JH, AB, DO, MC, EMM, MG, ID were funded by Open Targets. J.Z. and T.R.G were funded by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/4). JSh and GJW were funded by the Wellcome Trust Grant 206194. This research was funded in part by the Wellcome Trust [Grant 206194]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. |
format | Online Article Text |
id | pubmed-8457835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-84578352021-09-24 A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance Anisul, Mohd Shilts, Jarrod Schwartzentruber, Jeremy Hayhurst, James Buniello, Annalisa Shaikho Elhaj Mohammed, Elmutaz Zheng, Jie Holmes, Michael Ochoa, David Carmona, Miguel Maranville, Joseph Gaunt, Tom R Emilsson, Valur Gudnason, Vilmundur McDonagh, Ellen M Wright, Gavin J Ghoussaini, Maya Dunham, Ian eLife Epidemiology and Global Health BACKGROUND: The virus SARS-CoV-2 can exploit biological vulnerabilities (e.g. host proteins) in susceptible hosts that predispose to the development of severe COVID-19. METHODS: To identify host proteins that may contribute to the risk of severe COVID-19, we undertook proteome-wide genetic colocalisation tests, and polygenic (pan) and cis-Mendelian randomisation analyses leveraging publicly available protein and COVID-19 datasets. RESULTS: Our analytic approach identified several known targets (e.g. ABO, OAS1), but also nominated new proteins such as soluble Fas (colocalisation probability >0.9, p=1 × 10(-4)), implicating Fas-mediated apoptosis as a potential target for COVID-19 risk. The polygenic (pan) and cis-Mendelian randomisation analyses showed consistent associations of genetically predicted ABO protein with several COVID-19 phenotypes. The ABO signal is highly pleiotropic, and a look-up of proteins associated with the ABO signal revealed that the strongest association was with soluble CD209. We demonstrated experimentally that CD209 directly interacts with the spike protein of SARS-CoV-2, suggesting a mechanism that could explain the ABO association with COVID-19. CONCLUSIONS: Our work provides a prioritised list of host targets potentially exploited by SARS-CoV-2 and is a precursor for further research on CD209 and FAS as therapeutically tractable targets for COVID-19. FUNDING: MAK, JSc, JH, AB, DO, MC, EMM, MG, ID were funded by Open Targets. J.Z. and T.R.G were funded by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/4). JSh and GJW were funded by the Wellcome Trust Grant 206194. This research was funded in part by the Wellcome Trust [Grant 206194]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. eLife Sciences Publications, Ltd 2021-08-17 /pmc/articles/PMC8457835/ /pubmed/34402426 http://dx.doi.org/10.7554/eLife.69719 Text en © 2021, Anisul et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Epidemiology and Global Health Anisul, Mohd Shilts, Jarrod Schwartzentruber, Jeremy Hayhurst, James Buniello, Annalisa Shaikho Elhaj Mohammed, Elmutaz Zheng, Jie Holmes, Michael Ochoa, David Carmona, Miguel Maranville, Joseph Gaunt, Tom R Emilsson, Valur Gudnason, Vilmundur McDonagh, Ellen M Wright, Gavin J Ghoussaini, Maya Dunham, Ian A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance |
title | A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance |
title_full | A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance |
title_fullStr | A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance |
title_full_unstemmed | A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance |
title_short | A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance |
title_sort | proteome-wide genetic investigation identifies several sars-cov-2-exploited host targets of clinical relevance |
topic | Epidemiology and Global Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457835/ https://www.ncbi.nlm.nih.gov/pubmed/34402426 http://dx.doi.org/10.7554/eLife.69719 |
work_keys_str_mv | AT anisulmohd aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT shiltsjarrod aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT schwartzentruberjeremy aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT hayhurstjames aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT bunielloannalisa aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT shaikhoelhajmohammedelmutaz aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT zhengjie aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT holmesmichael aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT ochoadavid aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT carmonamiguel aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT maranvillejoseph aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT gaunttomr aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT emilssonvalur aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT gudnasonvilmundur aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT mcdonaghellenm aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT wrightgavinj aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT ghoussainimaya aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT dunhamian aproteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT anisulmohd proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT shiltsjarrod proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT schwartzentruberjeremy proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT hayhurstjames proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT bunielloannalisa proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT shaikhoelhajmohammedelmutaz proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT zhengjie proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT holmesmichael proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT ochoadavid proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT carmonamiguel proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT maranvillejoseph proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT gaunttomr proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT emilssonvalur proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT gudnasonvilmundur proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT mcdonaghellenm proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT wrightgavinj proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT ghoussainimaya proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance AT dunhamian proteomewidegeneticinvestigationidentifiesseveralsarscov2exploitedhosttargetsofclinicalrelevance |